The Journal of Neuropsychiatry and Clinical Neurosciences
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
J Neuropsychiatry Clin Neurosci 17:447-454, November 2005
doi: 10.1176/appi.neuropsych.17.4.447
© 2005 American Neuropsychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Schiffer, R.
* Articles by Pope, L. E.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Schiffer, R.
* Articles by Pope, L. E.
Related Collections
* Other Treatment
* Antidepressants

Special Article

Review of Pseudobulbar Affect Including a Novel and Potential Therapy

Randolph Schiffer, M.D. and Laura E. Pope, Ph.D.

Received July 6, 2004; revised October 8, 2004; accepted October 29, 2004. From the Department of Neuropsychiatry, Texas Tech University, Health Sciences Center, Lubbock, Texas; Avanir Pharmaceuticals, San Diego, California. Address correspondence to Dr. Schiffer, Department of Neuropsychiatry Texas Tech University, Health Sciences Center 4515 11th St., Lubbock, TX; randolph.schiffer{at}ttuhsc.edu (E-mail).

Pseudobulbar affect (PBA) is an affective disinhibition syndrome associated with various neuropathologies, which is characterized by involuntary and inappropriate outbursts of laughter and/or crying. The PBA syndrome can be socially and occupationally disabling, and it is largely unrecognized in clinical settings. Validated instruments to distinguish PBA from other disorders of affective regulation exist and could be used to improve recognition of the disorder. There is no pharmacological therapy with a Food and Drug Administration indication for PBA, although antidepressants and dopaminergic agents have been reported to show varying levels of treatment success. Recent evidence suggests that treatment with a fixed combination of dextromethorphan and the cytochrome P450 2D6 enzyme inhibitor, quinidine, can improve PBA. This review describes the clinical and neuropathological features of PBA, and presents an overview of current and future treatment approaches.




This article has been cited by other articles:


Home page
J. Neuropsychiatry Clin. Neurosi.Home page
J. Parvizi and R. Schiffer
Exaggerated Crying and Tremor With a Cerebellar Cyst
J Neuropsychiatry Clin Neurosci, May 1, 2007; 19(2): 187 - 190.
[Abstract] [Full Text] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 2005 American Neuropsychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Neuropsychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org